HABA Laboratories, Inc. (4925) AI Stock Analysis

• Market Cap: ¥6.60B
• Dividend Yield: 2.29%
• Average Volume (3M): 1.56K
• Price to Earnings (P/E): 10.3
• Beta (1Y): 0.24
• Revenue Growth: -3.27%
• EPS Growth: N/A
• Country: JP
• Employees: 631
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 10.87
• Shares Outstanding: 3,935,000
• 10 Day Avg. Volume: 1,500
• 30 Day Avg. Volume: 1,556
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,780.00
• Price Target Upside: 2.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: ¥1,780.00 ▲(2.06% Upside)

HABA Laboratories' overall stock score is driven by a strong valuation due to a low P/E ratio and attractive dividend yield. However, financial performance is mixed, with strong balance sheet stability but challenges in revenue growth and profitability. Technical analysis indicates a neutral to slightly bearish trend, with potential overbought conditions. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Balance Sheet Strength

A strong balance sheet with low leverage and solid equity provides financial stability, reducing risks and supporting long-term growth initiatives.

Cash Flow Improvement

Improving operating cash flow indicates enhanced cash generation ability, which can support reinvestment in the business and shareholder returns.

Brand Reputation

A strong brand reputation for safety and quality helps maintain customer loyalty and supports long-term revenue stability and growth.

Negative Factors

Revenue Decline

A declining revenue trend can hinder the company's ability to invest in growth and innovation, impacting future competitiveness and market position.

Inconsistent Profitability

Fluctuating net income and inconsistent profitability can undermine financial predictability, affecting investor confidence and strategic planning.

Free Cash Flow Volatility

Volatile free cash flow growth can limit the company's ability to fund new projects and return capital to shareholders, impacting long-term financial health.

HABA Laboratories, Inc. Business Overview & Revenue Model

Company Description

HABA Laboratories, Inc. (4925) is a Japanese company that specializes in the development, manufacturing, and sale of cosmetics and skincare products. The company is known for its commitment to using additive-free ingredients, catering to customers who prioritize safety and quality in their beauty products. HABA Laboratories focuses on providing high-quality skincare solutions and has established a strong presence in the Japanese market, with a growing international footprint.

How the Company Makes Money

HABA Laboratories, Inc. generates revenue primarily through the sale of its skincare and cosmetic products. The company's key revenue streams include direct sales through its retail stores and online platforms, as well as distribution through third-party retailers and partners. HABA Laboratories leverages its brand reputation for safety and quality to attract and retain a loyal customer base. The company also engages in marketing and promotional activities to expand its market reach and increase sales. Strategic partnerships with retailers and distributors help HABA Laboratories to extend its product availability and enhance its earnings potential.

HABA Laboratories, Inc. Financial Statement Overview

Summary

HABA Laboratories shows a mixed financial picture. The income statement is pressured by revenue declines and inconsistent profitability, while the balance sheet is strong with low leverage and solid equity. Cash flow generation is improving, but historical volatility presents challenges. The company demonstrates resilience in its financial stability but needs to address profitability and growth concerns.

Income Statement

HABA Laboratories has faced challenges with revenue growth, showing an overall declining trend from the 2020 peak. The gross profit margin remains robust, suggesting efficient cost management, but net income has fluctuated significantly, impacting net profit margins negatively in recent years. The EBIT and EBITDA margins have been erratic, reflecting operational challenges and inconsistent profitability.

Balance Sheet

The balance sheet shows strong equity with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is low, reducing leverage risks. However, the return on equity is unstable due to fluctuating net income. Overall, the company maintains a solid asset base with a strong equity cushion.

Cash Flow

Cash flow analysis reveals improving operating cash flow in the most recent period, which is a positive sign. Yet, the company has struggled with free cash flow growth, and previous periods showed volatility. The operating cash flow to net income ratio indicates better cash generation relative to profits recently, but historical instability remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.06B	12.06B	12.32B	12.04B	12.91B	14.31B
Gross Profit	8.09B	7.99B	8.03B	8.17B	8.79B	10.20B
EBITDA	811.56M	811.56M	-1.31B	17.05M	448.30M	960.14M
Net Income	575.66M	576.57M	-2.12B	-707.87M	-269.03M	216.42M
Balance Sheet
Total Assets	12.34B	12.34B	12.43B	14.66B	15.69B	17.44B
Cash, Cash Equivalents and Short-Term Investments	4.74B	4.74B	3.96B	4.82B	5.65B	5.66B
Total Debt	1.82B	1.82B	2.36B	2.03B	2.56B	3.92B
Total Liabilities	3.42B	3.42B	3.92B	3.88B	4.05B	5.40B
Stockholders Equity	8.93B	8.93B	8.51B	10.77B	11.64B	12.04B
Cash Flow
Free Cash Flow	0.00	1.48B	-1.02B	-232.69M	1.53B	-346.95M
Operating Cash Flow	0.00	1.62B	-587.92M	55.96M	1.71B	534.71M
Investing Cash Flow	0.00	-147.18M	-441.79M	-214.40M	-216.49M	-925.08M
Financing Cash Flow	0.00	-689.49M	171.06M	-676.32M	-1.51B	825.38M

HABA Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1744.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Positive. The current price of 1744 is above the 20-day moving average (MA) of 1734.60, above the 50-day MA of 1685.58, and above the 200-day MA of 1691.75, indicating a bullish trend. The MACD of 16.71 indicates Positive momentum. The RSI at 64.55 is Neutral, neither overbought nor oversold. The STOCH value of 56.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4932	80 Outperform	¥11.74B	23.23		5.60%	27.84%	51.43%
4936	65 Neutral	¥12.80B	62.88		1.96%	4.75%	-83.63%
4925	63 Neutral	¥6.60B	10.31		2.29%	-3.27%	―
Sector *	62 Neutral	$20.56B	14.66	-3.18%	3.15%	1.93%	-6.58%
4929	60 Neutral	¥6.16B	159.76		1.56%	-9.81%	―
4934	56 Neutral	¥7.82B	16.61		―	-17.95%	―
4926	45 Neutral	¥5.16B	20.49		1.66%	7.21%	―